drugset

drugset / Trial / NCT05326347

A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia

NCT05326347 ↗

Phase 3 Active not recruiting 190 enrolled Otsuka Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

Confirm the tolerability and safety of long-term administration of the brexpiprazole QW formulation in patients with schizophrenia

Timeline

Start: 2022-05-31
Primary completion: 2025-08
Completion: 2025-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brexpiprazole	Small molecule	48 mg	Oral

Indications